Skip to main content
. 2021 Jan 19;10(1):12. doi: 10.1038/s41389-020-00300-z

Fig. 6. Combined Akt1/2 inhibition and chemotherapy inhibits stemness and tumor growth in vivo.

Fig. 6

A Western blot confirmation of Akt1/2 knockdown by shRNA in HT1080 cells. B Growth of HT1080 fibrosarcoma xenografts stably transduced with sh.Scr or sh.Akt1/2 in athymic nude mice treated and PBS or doxorubicin. C Photos of representative tumors. D Immunohistochemical analysis of tumors for proliferation using Ki67 (green), stemness using CD133 (green) and Nanog (white), and apoptosis using cleaved caspase-3 (red) and Bcl-2 (yellow). E Immunohistochemical staining of commercially available tissue array slide containing 79 human sarcomas and 4 human normal tissues for CD133, Nanog, and p-Akt1/2 (S473). β-Actin, loading control. Scale bar, 50 µm. *p < 0.01 compared to control.